QLG-RISK3
Research type
Research Study
Full title
Development of an EORTC questionnaire for individuals at risk for a Hereditary Cancer Predisposition Syndrome: the EORTC QLQ-HCPSxx (Phase 3)
IRAS ID
325435
Contact name
Mieke Van Hemelrijck
Contact email
Sponsor organisation
King's College London
Duration of Study in the UK
2 years, 6 months, 1 days
Research summary
The European Organisation of Research and Treatment of Cancer’s Quality of Life Group (EORTC QLG) has developed a four-phase framework that can be used to develop and validate quality of life questionnaires for individuals with cancer. These are developed as modules to supplement their existing EORTC core quality of life questionnaire, the ‘QLQ-C30’. For example, modules have previously been developed for endometrial cancer (QLQEN24), bone metastases (QLQ-BM22), and cancer-related fatigue (QLQ-FA12). The four-phase approach comprises a literature review followed by interviews with patients and clinicians (Phase 1), construction of a questionnaire (Phase 2), refinement of the questionnaire (Phase 3), and finally administration of the questionnaire to an international sample in a full validation study (Phase 4).
The present study aims to contribute to the development of a module designed to measure quality of life in individuals at risk for a hereditary cancer predisposition syndrome. The study aims to undertake Phase 3 of the above module development process.REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
23/LO/0785
Date of REC Opinion
9 Oct 2023
REC opinion
Favourable Opinion